Status:
COMPLETED
Evaluation of Thiosulfate in End Stage Renal Disease and Kidney Transplantation
Lead Sponsor:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Conditions:
End Stage Renal Disease (ESRD)
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Kidneys retrieved from deceased donors will be randomized for conventional perfusion (University of Wisconsin: UW) with or without supplementation of thiosulfate, a major H2S metabolite, and transpl a...
Detailed Description
The rise in the incidence of end stage renal disease (ESRD) is both a national and international concern. Renal transplantation is currently the best available treatment for established renal failure ...
Eligibility Criteria
Inclusion
- \- All patients \>18years old who are being considered for renal transplantation at LHSC that are receiving a DCD kidney.
Exclusion
- Age \<18 years old
- Inability to give informed consent,
- Patients receiving kidneys from living donors
- Patients with known hypersensitivity to either SEACALPHYX or to any of the ingredients contained within.
- Pregnant women.
- Patients with sulfite allergies
Key Trial Info
Start Date :
March 21 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2022
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT04292184
Start Date
March 21 2021
End Date
November 1 2022
Last Update
December 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
London Health Sciences Centre, University Hospital
London, Ontario, Canada, N6A 5A5